Kexi Wang

Kexi Wang

Associate

Technology Transactions

Dr. Kexi Wang is an associate in the Shanghai office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions and corporate law. Prior to attending law school, Kexi conducted doctoral research on the regulatory mechanism of mitosis, where she gained research experience in cell biology, molecular biology, and biochemistry.

Experience

Education

J.D., Harvard Law School, 2019Cum Laude
Ph.D., Biology, University of Toledo, 2014
B.S., Medical Laboratory Tests and Analysis, Shanghai Jiaotong University, School of Medicine, 2009

Admissions

State Bar of California

Credentials

Education

J.D., Harvard Law School, 2019Cum Laude
Ph.D., Biology, University of Toledo, 2014
B.S., Medical Laboratory Tests and Analysis, Shanghai Jiaotong University, School of Medicine, 2009

Admissions

State Bar of California

Recent Insights

Client Highlights

On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:

Learn More

Client Highlights

On March 29, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.

Learn More

View All

Recent Events

Affiliated Programs

Wilson Sonsini is pleased to be a 2025 sponsor of the Pharmaceutical and Biomedical Sciences Society International (PBSS).

Learn More